You are here

Roche

Roche’s Genentech partners with Nvidia in AI drug deal

Roche’s Genentech partners with Nvidia in AI drug deal

BioPharma Dive

artificial intelligence

Flag link:

A year after Roche's Alzheimer's failure, scientists reflect on what could have been

A year after Roche's Alzheimer's failure, scientists reflect on what could have been

Fierce Biotech

Alzheimer's disease

Flag link:

European regulator endorses high-dose version of Bayer eye drug Eylea

European regulator endorses high-dose version of Bayer eye drug Eylea

Reuters

Flag link:

Regeneron touts launch of high-dose Eylea in battle with Roche's Vabysmo

Regeneron touts launch of high-dose Eylea in battle with Roche's Vabysmo

Fierce Pharma

Flag link:

Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says

Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says

BioPharma Dive

Flag link:

Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?

Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?

Motley Fool

ulcerative colitis

Crohn's Disease

Flag link:

FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

FDA Approves Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)

BioSpace

retinal vein occlusion

Flag link:

Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug

Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug

Reuters

Flag link:

Roche pays $7.1B to Roivant for rights to Telavant’s IBD candidate

Roche pays $7.1B to Roivant for rights to Telavant’s IBD candidate

BioSpace

ulcerative colitis

Crohn’s disease

Flag link:

Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options

Lung Cancer Takes Center Stage at ESMO Congress 2023 With New Drugs, More Options

OBR Oncology

non-small cell lung cancer

Flag link:

Roche drops oral eye disease drug after completing phase 2, pulls back from solid tumor bispecific

Roche drops oral eye disease drug after completing phase 2, pulls back from solid tumor bispecific

Fierce Biotech

diabetic retinopathy

bispecific antibodies

Flag link:

Roche's Q3 sales down 3% on currency headwinds, drop in COVID sales

Roche's Q3 sales down 3% on currency headwinds, drop in COVID sales

Reuters

Flag link:

Roche pays $50M upfront to Monte Rosa in molecular glue deal

Roche pays $50M upfront to Monte Rosa in molecular glue deal

Fierce Biotech

protein degradation

Flag link:

Roche builds gene therapy portfolio with SpliceBio deal

Roche builds gene therapy portfolio with SpliceBio deal

Pharmaphorum

Spark Therapeutics

inherited retinal disease

Flag link:

Amid Eylea showdown, Roche's Vabysmo shows durability in retinal vein occlusion

Amid Eylea showdown, Roche's Vabysmo shows durability in retinal vein occlusion

Fierce Pharma

retinal vein occlusion

Flag link:

Roche preps for filings after subcutaneous Ocrevus matches up to IV formulation in phase 3 study

Roche preps for filings after subcutaneous Ocrevus matches up to IV formulation in phase 3 study

Fierce Pharma

multiple sclerosis

clinical trials

Flag link:

Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment

Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment

BioSpace

clinical trials

Flag link:

Biogen nabs FDA nod for biosimilar version of Roche's blockbuster Actemra

Biogen nabs FDA nod for biosimilar version of Roche's blockbuster Actemra

Fierce Pharma

autoimmune disease

Flag link:

In label expansion bid, AbbVie and Roche's Venclexta falls short in multiple myeloma subset

In label expansion bid, AbbVie and Roche's Venclexta falls short in multiple myeloma subset

Fierce Pharma

Multiple Myeloma

Flag link:

Roche pays Ionis $60M upfront to license RNA-targeting Alzheimer's, Huntington's programs

Roche pays Ionis $60M upfront to license RNA-targeting Alzheimer's, Huntington's programs

Fierce Biotech

Ionis Pharmaceuticals

Alzheimer's disease

Huntington's disease

Flag link:

Pages